TTTatsuya Takenouchi

Tatsuya Takenouchi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tatsuya Takenouchi has a total of 224 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Post‐recurrence outcomes after observation or adjuvant anti‐ PD ‐1 therapy in nail apparatus melanoma

    by Takaya Komori, Eiji Nakano, Yukiko Kiniwa, Shoichiro Mori, Sotaro Yamamoto, Hiroshi Kato, Shusuke Yoshikawa, Koji Yoshino, Megumi Aoki, Tatsuya Takenouchi, et al.

  • Open Access

    Efficacy of Adjuvant Interferon‐β Versus Observation for Resected Nail Apparatus Melanoma: A Multicenter Retrospective Study

    by Takaya Komori, Eiji Nakano, Yukiko Kiniwa, Shoichiro Mori, Sotaro Yamamoto, Hiroshi Kato, Shusuke Yoshikawa, Koji Yoshino, Megumi Aoki, Tatsuya Takenouchi, et al.

    Nail apparatus melanoma (NAM) is a biologically and clinically distinct subtype of melanoma; however, the efficacy of adjuvant interferon (IFN) therapy in this population remains unclear. We conducted a multicenter retrospective study to compare adjuvant IFN‐β (adj‐IFN) with observation (OBS) in patients with resected stage IIB, IIC, or III NAM. We analyzed 282 Japanese patients treated at 42 institutions between 2014 and 2024. Recurrence–free survival (RFS) and distant metastasis–free survival (DMFS) were co‐primary outcomes, and overall survival (OS) was a secondary outcome. Survival outcomes were assessed using Kaplan–Meier analyses and Cox multivariable proportional hazards models. To minimize the differences of baseline characteristics between the two groups, propensity score matching (PSM) was applied. In multivariable Cox analyses, adj‐IFN showed improved RFS (HR 0.67, 95% CI 0.45–0.998, p = 0.049), while no statistically significant benefits were observed for DMFS (HR 0.66, 95% CI 0.42–1.01, p = 0.06) or OS (HR 0.85, 95% CI 0.54–1.35, p = 0.50) compared with OBS. After PSM (71 patients per group), survival outcomes were comparable between the two groups, with no statistical significance in RFS (HR 0.71, 95% CI 0.45–1.12, p = 0.14), DMFS (HR 0.73, 95% CI 0.44–1.20, p = 0.22), or OS (HR 1.01, 95% CI 0.58–1.78, p = 0.96). In conclusion, no significant survival advantage of adj‐IFN over observation was demonstrated in the matched cohort. Although a borderline association with improved RFS was observed in the overall cohort, this finding did not translate into consistent benefit across endpoints. Further prospective evidence, including the final results of the randomized phase III trial (JCOG1309, J‐FERON), is required to clarify the clinical role of adj‐IFN in NAM.

  • Tumor‐Related Determinants of Reconstructive Method After Excision of Facial Basal Cell Carcinoma

    by Kazutoshi Nishimura, Anri Kimura, Anna Nakamura, Sumiko Takatsuka, Tatsuya Takenouchi

    Basal cell carcinoma (BCC) is increasingly encountered in the context of population aging in Japan, and facial lesions frequently require reconstruction to preserve both function and appearance. This retrospective study analyzed 1149 facial BCCs treated with surgical excision at a single cancer center to describe reconstructive patterns and to identify factors influencing reconstructive method. Overall, local flap was the most frequently used reconstructive modality, followed by primary closure, skin graft, and secondary intention healing. In univariate analyses, tumors located at anatomical free‐margin sites, larger tumor diameter, and aggressive histopathological subtypes were associated with increased use of flap or graft reconstruction. To identify factors independently associated with reconstructive method in clinically relevant settings, multivariate logistic regression analysis was performed among 649 cases in which primary closure was not feasible, comparing skin graft versus local flap reconstruction. Tumor diameter and histopathological subtype remained independently associated with reconstructive method. Specifically, larger tumor diameter and aggressive histopathological subtypes were independently associated with selection of skin graft reconstruction, whereas patient age, sex, and tumor location were not. These findings suggest that, when primary closure is not an option, tumor‐centered factors—particularly tumor size and histopathological subtype—are associated with reconstructive strategy for facial BCC.


  • Phase III Study Investigating the Safety and Efficacy of TM5614 in Combination With Nivolumab for the Treatment of Unresectable Malignant Melanoma: Protocol

    by Taku Fujimura, Koji Yoshino, Hiroshi Kato, Satoshi Fukushima, Yasuhiro Fujisawa, Shigeto Matsushita, Hisashi Uhara, Daiki Rokunohe, Tatsuya Takenouchi, Takeo Maekawa, et al.

    TM5614, a plasminogen activator inhibitor‐1 (PAI‐1) inhibitor, has demonstrated potential in overcoming nivolumab resistance in patients with unresectable, anti‐PD‐1 antibody‐refractory malignant melanoma. Previous Phase II trials have shown promising response rates, warranting further investigation through a randomised, placebo‐controlled Phase III trial. This Phase III, randomised, double‐blind, placebo‐controlled, investigator‐initiated clinical trial aims to evaluate the efficacy and safety of TM5614 in combination with nivolumab for treating patients with unresectable, anti‐PD‐1 antibody‐refractory malignant melanoma. The study will enrol 124 participants across 18 medical institutions in Japan. Patients will receive either TM5614 plus nivolumab or placebo plus nivolumab for 48 weeks. The primary endpoint is overall survival (OS), while secondary endpoints include objective response rate (ORR), progression‐free survival (PFS), disease control rate (DCR), and the incidence of treatment‐related adverse events. This study is designed to compare OS between the TM5614 plus nivolumab group and the placebo plus nivolumab group. Statistical analyses will be conducted using the Kaplan–Meier method and Cox proportional hazards models. This Phase III trial will provide critical insights into the efficacy of TM5614 in combination with nivolumab as a novel treatment strategy for unresectable, anti‐PD‐1 antibody‐refractory malignant melanoma. The results may offer new therapeutic options to improve patient outcomes and overcome resistance to immune checkpoint inhibitors. Trial Registration: jRCT2021240049 ( https://jrct.niph.go.jp/en‐latest‐detail/jRCT2021240049 ). Protocol version: Ver.1.2 (3rd February, 2025)


  • Open Access

    Clinical characteristics and treatments of Merkel cell carcinoma in Japan: A multi-center retrospective study

    by Eiji Nakano, Motoki Nakamura, Shuichi Ohe, Shusuke Kawashima, Ayano Maruyama, Wataru Omata, Takamichi Ito, Yuki Yamamoto, Akira Kaneko, Kenta Nakama, et al.


  • Open Access

    Comparing 2 cm vs. 1 cm surgical margins in acral melanoma of the sole with Breslow thickness greater than 2 mm: A multicenter retrospective study of 336 Japanese patients

    by Shigeru Koizumi, Naoya Yamazaki, Yuki Ichigozaki, Hiroshi Kitagawa, Yukiko Kiniwa, Sayuri Sato, Toshihiro Takai, Reiichi Doi, Takamichi Ito, Masahito Yasuda, et al.


  • Impact of Surgical Delay on Prognosis in Patients With Cutaneous Melanoma: A Single‐Institution Retrospective Study in Japan

    by Kazutoshi Nishimura, Anri Kimura, Anna Nakamura, Sumiko Takatsuka, Tatsuya Takenouchi

    This study investigated the relationship between surgical interval and prognosis in Japanese patients with cutaneous melanoma. A retrospective analysis was conducted on 319 cases of Stage I–III primary cutaneous melanoma treated with curative surgery at Niigata Cancer Center Hospital between 1998 and 2020. Patients were stratified into two groups based on surgical interval: less than 30 days and 30 days or longer. The impact on recurrence‐free survival (RFS) and overall survival (OS) was analyzed. Overall, no significant differences in RFS or OS were observed between the two groups. However, subgroup analysis by stage revealed a trend toward improved RFS and OS in Stage II patients with a surgical interval of less than 30 days, though this difference did not reach statistical significance. Multivariate analysis did not identify surgical interval as an independent prognostic factor for RFS or OS. In conclusion, surgical interval did not significantly impact overall prognosis in this cohort. However, the observed trend in Stage II Japanese patients suggests a potential association, warranting further investigation to validate these findings.

  • Reevaluating hybrid neurofibroma/schwannoma: Predominance of schwannoma features despite CD34 positivity and initial neurofibroma diagnosis

    by Tatsuya Katsumi, Ryota Hayashi, Shingo Takei, Osamu Ansai, Sumiko Takatsuka, Tatsuya Takenouchi, Kyota Saito, Kazuaki Suda, Kosuke Yoshihara, Takahiro Nagai, et al.

    Schwannomas consist of both high‐cellularity regions (Antoni A area) and hypocellular regions (Antoni B area) in histopathological findings. Neurofibromas characteristically consist of CD34 positive spindle cells with thin, wavy, nuclei and wavy collagen bands. Previous reports have described segments of schwannomas with neurofibroma features as hybrid tumors, although hybrid tumors were diagnosed based on partial CD34 positivity in many previous reports. On the other hand, the Antoni B area of some schwannomas was reported to be positive for CD34. Therefore, the definition of a hybrid tumor has not been clear. The objective of this study was to determine whether only CD34 positive findings in schwannomas could be used to define a hybrid tumor. In the analysis of our patient with schwannomatosis caused by a novel LZTR1 germline mutation, part of the tumor had CD34 positive hypocellular regions. These regions contained no thin, wavy, nuclei, indicating an Antoni B area. Laser microdissection was used to investigate the genetic background and differences in molecular mechanisms between CD34 positive and CD34 negative regions. All mutations identified in CD34 positive regions were also found in CD34 negative regions. Our data could not clear the genetic background of Antoni B which was CD34 positive area. We then reviewed the pathologies of 66 sporadic schwannomas. Histopathological examinations of all schwannomas revealed the absence of thin, wavy, nuclei and wavy collagen bands, and no hybrid tumors were found in any of the cases. Ten of 66 patients were randomly selected for CD34 immunostaining and positivity was found in all cases. Our data suggest that it is difficult to distinguish schwannomas by staining for CD34 alone, as Antoni B areas can also be positive for CD34. Therefore, CD34 staining alone should not be used to diagnose hybrid tumors in patients with schwannomas.